Pre-operative serum TSH levels: A risk factor for advanced metastatic differentiated thyroid carcinoma.

American Joint Committee on Cancer (AJCC) Differentiated thyroid cancer (DTC) Fine needle aspiration cytology (FNAC) TSH levels Thyroid cancer

Journal

Pakistan journal of medical sciences
ISSN: 1682-024X
Titre abrégé: Pak J Med Sci
Pays: Pakistan
ID NLM: 100913117

Informations de publication

Date de publication:
Historique:
entrez: 7 9 2019
pubmed: 7 9 2019
medline: 7 9 2019
Statut: ppublish

Résumé

As the thyroid cancer incidence is increasing, the search for its risk factor is becoming more important. Serum thyroid stimulating hormone (TSH) levels being a growth factor for normal thyroid tissue, is also considered as growth promotor of cancer cells. In our study we aimed for pre-operative serum TSH levels of Differentiated thyroid cancers (DTC) done before their first surgery and determined its association with advanced disease in terms of stage, multifocal disease, lymph node involvement and distant metastasis. We have conducted a retrospective review of thyroid cancers from 1 Out of 147 participants, 89.4% had papillary carcinoma or its variants whereas 10.6% reported follicular carcinoma. The mean pre-op TSH level of the patients included was 2.04 ± 1.79. In addition to the descriptive analysis, the univariate regression analysis revealed that the association of serum TSH levels was found to be statistically insignificant with advanced stage of thyroid cancer, multifocal disease, lymph node metastasis and distant metastasis respectively. The serum TSH levels before surgery was not associated with poor prognosis of differentiated thyroid cancer with respect to higher staging, multifocal disease, lymphatic or distant metastasis.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
As the thyroid cancer incidence is increasing, the search for its risk factor is becoming more important. Serum thyroid stimulating hormone (TSH) levels being a growth factor for normal thyroid tissue, is also considered as growth promotor of cancer cells. In our study we aimed for pre-operative serum TSH levels of Differentiated thyroid cancers (DTC) done before their first surgery and determined its association with advanced disease in terms of stage, multifocal disease, lymph node involvement and distant metastasis.
METHODS METHODS
We have conducted a retrospective review of thyroid cancers from 1
RESULTS RESULTS
Out of 147 participants, 89.4% had papillary carcinoma or its variants whereas 10.6% reported follicular carcinoma. The mean pre-op TSH level of the patients included was 2.04 ± 1.79. In addition to the descriptive analysis, the univariate regression analysis revealed that the association of serum TSH levels was found to be statistically insignificant with advanced stage of thyroid cancer, multifocal disease, lymph node metastasis and distant metastasis respectively.
CONCLUSION CONCLUSIONS
The serum TSH levels before surgery was not associated with poor prognosis of differentiated thyroid cancer with respect to higher staging, multifocal disease, lymphatic or distant metastasis.

Identifiants

pubmed: 31488998
doi: 10.12669/pjms.35.5.704
pii: PJMS-35-1312
pmc: PMC6717463
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1312-1317

Déclaration de conflit d'intérêts

Conflict of interest: None.

Références

J Pak Med Assoc. 2004 Oct;54(10):526-8
pubmed: 15552288
Nat Clin Pract Endocrinol Metab. 2006 Jul;2(7):384-94
pubmed: 16932321
J Clin Endocrinol Metab. 2008 Mar;93(3):809-14
pubmed: 18160464
Clin Endocrinol (Oxf). 2009 Sep;71(3):434-9
pubmed: 19067720
Endocr Relat Cancer. 2009 Dec;16(4):1251-60
pubmed: 19528244
Hematol Oncol Stem Cell Ther. 2009;2(2):345-8
pubmed: 20118058
Arch Otolaryngol Head Neck Surg. 2010 Nov;136(11):1055-61
pubmed: 21079156
Endocrine. 2011 Jun;39(3):259-65
pubmed: 21161440
Clin Endocrinol (Oxf). 2013 Mar;78(3):472-7
pubmed: 22924613
Am J Otolaryngol. 2013 Jul-Aug;34(4):312-9
pubmed: 23357595
J Clin Endocrinol Metab. 2014 Oct;99(10):3686-93
pubmed: 25062456
Int J Cancer. 2015 May 1;136(9):2187-95
pubmed: 25284703
Am Health Drug Benefits. 2015 Feb;8(1):30-40
pubmed: 25964831
Caspian J Intern Med. 2012 Winter;3(1):359-62
pubmed: 26557286
Thyroid. 2017 Jun;27(6):751-756
pubmed: 28463585
Int J Endocrinol. 2017;2017:7053959
pubmed: 28572820
World J Nucl Med. 2017 Jul-Sep;16(3):202-205
pubmed: 28670178
Med Arch. 2018 Apr;72(2):108-111
pubmed: 29736098

Auteurs

Sumera Batool (S)

Dr. Sumera Batool, FCPS. Department of Endocrinology, Agha Khan University Hospital, Karachi, Pakistan.

Muhammad Shakir Afridi (MS)

Dr. Muhammad Shakir Afridi, Final year student MBBS, Agha Khan University Hospital, Karachi, Pakistan.

Adeel Khoja (A)

Dr. Adeel Khoja, MBBS, MSc. Department of Endocrinology, Agha Khan University Hospital, Karachi, Pakistan.

Najmul Islam (N)

Dr. Najmul Islam, FRCP. Department of Endocrinology, Agha Khan University Hospital, Karachi, Pakistan.

Classifications MeSH